4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Hallym University Medical Center.
Recruitment status was Not yet recruiting
Information provided by (Responsible Party):
Hallym University Medical Center
First received: September 29, 2010
Last updated: October 4, 2011
Last verified: September 2010
Data on 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene are limited in Asian patients with sepsis. Therefore, the investigators aim to prospectively investigate the incidence of 4G/5G polymorphism and its relationship with disseminated intravascluar coagulatin in patients with severe sepsis and septic shock.
||Observational Model: Cohort
Time Perspective: Prospective
||Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene
Biospecimen Retention: Samples With DNA
Blood sample for 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1)
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||September 2012 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients admitted to the ICU for severe sepsis or septic shock
- Adult patinents aged > 18 years, Patients satisfying the criteria by 2008 Surviving Sepsis Campagin, Patients who are determined as having a sepsis within 24 hours of ICU stay
- Do-not-resuscitate, cardiopulmonary resuscitation, ICU stay < 1 day, Refusal to participate in the study, Hematologic malignancy or liver cirrhosis (Child C), Congenital abnormality in coagulation system, Transfer from other ICUs or hospitals
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Hallym University Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 29, 2010
||October 4, 2011
||Korea: Food and Drug Administration
Keywords provided by Hallym University Medical Center:
plasminogen activator inhibitor,
disseminated intravascular coagulation,
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 22, 2014
Disseminated Intravascular Coagulation
Blood Coagulation Disorders
Systemic Inflammatory Response Syndrome
Plasminogen Activator Inhibitor 1
Molecular Mechanisms of Pharmacological Action
Serine Proteinase Inhibitors